BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 32333398)

  • 1. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.
    Sriram K; Insel PA
    Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
    Young MJ; Clyne CD; Chapman KE
    J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covid-19: the renin-angiotensin system imbalance hypothesis.
    Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
    Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
    Sinha S; Sehgal A; Sehgal R
    Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
    Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.
    Gurwitz D
    Drug Dev Res; 2020 Aug; 81(5):537-540. PubMed ID: 32129518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19, ACE2, and the cardiovascular consequences.
    South AM; Diz DI; Chappell MC
    Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1084-H1090. PubMed ID: 32228252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
    Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
    J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
    Steckelings UM; Sumners C
    Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
    Hooper NM; Lambert DW; Turner AJ
    Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.
    Ferrario CM; Ahmad S; Groban L
    Clin Sci (Lond); 2020 Oct; 134(19):2645-2664. PubMed ID: 33063823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
    Nicolau LAD; Magalhães PJC; Vale ML
    Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 19. Apelin-potential therapy for COVID-19?
    Saeedi Saravi SS; Beer JH
    J Mol Cell Cardiol; 2020 Aug; 145():84-87. PubMed ID: 32562701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.